ArticleResearch square2025
Development and Validation of Survival Scores and the Assessment of Spatial Trends in End-Stage Kidney Disease Outcomes.
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: There is a need to create new mortality prediction models for end-stage kidney disease (ESKD). This study aimed to develop and validate survival scores for patients with ESKD using a mixture cure model (MCM) including assessing the spatial trends in ESKD outcomes. Methods: This study used a United States Renal Data System (USRDS) dataset that contains 2,228,693 people with incident ESKD from 2000 through 2020, including those on dialysis or had at least one transplant. Many variables, including demographic and comorbid factors, were included within an MCM. This MCM was used to develop seven survival scores that would be summarized geographically. These survival scores are shown using maps of the United States and validated using the clinical measurements found within the USRDS dataset. Results: Many spatial survival trends across the United States were observed that could be validated using the USRDS data and current literature. The Appalachian and Great Plains regions of the United States contained individuals who mostly had lower survivability. Conversely, individuals residing around Southern California, in the Southeast, and around the Texas-Mexico border had higher survivability. Most of these findings aligned with previous studies. Furthermore, many of the trends could be explained by both the coefficient estimates of the MCM and the characteristics of the individuals living in each region. For example, the MCM coefficient estimates found Hispanics to have a higher survivability than their non-Hispanic counterparts, which aligned with the predominantly Hispanic-populated area of the Texas-Mexico border. Lastly, serum creatine, a USRDS variable not used within the MCM, was found to have a moderately positive, linear relationship with the survival scores developed. Conclusions: The survival scores developed and validated may benefit practitioners and policy-makers in more effectively addressing ESKD disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.